A nurse is reviewing the laboratory values of a client with bone marrow suppression and is receiving epoetin alfa. Which of the following values would indicate an improvement in the client's condition?

Bone marrow suppression leads to decreased production of blood components, including red blood cells, white blood cells, and platelets. The specific abnormality depends on the affected cell line. Epoetin alfa is used to stimulate red blood cell production in the bone marrow, particularly in clients with anemia related to chronic kidney disease, chemotherapy, or bone marrow suppression. Therefore, improvement is best reflected by an increase in hemoglobin levels. Rationale: A. A WBC count of 4,800 mm³ indicates a normal or near-normal white blood cell level, but it does not reflect the therapeutic effect of epoetin alfa. This medication does not stimulate leukocyte production. WBC changes are more relevant to growth factors like filgrastim, not erythropoiesis-stimulating agents. B. A WBC count of 500 mm³ indicates severe neutropenia and significant bone marrow suppression. This reflects a high risk for infection and does not demonstrate improvement. It is unrelated to the action of epoetin alfa, which targets red blood cell production. C. A hemoglobin level of 11.5 g/dL indicates improvement because epoetin alfa stimulates erythropoiesis, increasing red blood cell production. This rise in hemoglobin suggests improved oxygen-carrying capacity and reduced anemia. It reflects the intended therapeutic outcome of the medication. D. A platelet count of 150,000 mm³ is within normal limits but does not reflect the action of epoetin alfa. Platelet production is regulated by different mechanisms and medications such as thrombopoietin agonists or oprelvekin. Therefore, it is not an appropriate indicator of response to epoetin alfa therapy.